| P50 | author | Brian Druker | Q373427 |
| | Kevin Watanabe-Smith | Q42544817 |
| | Monika A Davare | Q64503291 |
| P2093 | author name string | A Agarwal | |
| | R M Braziel | |
| | B Park | |
| | C A Eide | |
| | J W Tyner | |
| | S Mongoue-Tchokote | |
| | C E Tognon | |
| | R J MacKenzie | |
| P2860 | cites work | Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease | Q24617270 |
| | Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 | Q27687464 |
| | Exploration, normalization, and summaries of high density oligonucleotide array probe level data | Q27861098 |
| | Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells | Q28250509 |
| | RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia | Q33306326 |
| | JAK and MPL mutations in myeloid malignancies | Q33378737 |
| | Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain | Q33890593 |
| | Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited | Q34181570 |
| | New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway. | Q34412332 |
| | JAK/STAT signaling in hematological malignancies. | Q34641224 |
| | CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP | Q34667760 |
| | MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia | Q34770384 |
| | Leukemic cells and the cytokine patchwork | Q35643667 |
| | A new modality for immunosuppression: targeting the JAK/STAT pathway | Q35825869 |
| | In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction | Q36366827 |
| | Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity | Q36483460 |
| | The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes | Q36508949 |
| | IL-3, IL-5, and GM-CSF signaling: crystal structure of the human beta-common receptor | Q36617062 |
| | Acute myeloid leukaemia | Q36663603 |
| | Aberrant cytokine signaling in leukemia | Q36970192 |
| | Mining for JAK-STAT mutations in cancer | Q37091361 |
| | Chemokine signaling in cancer: one hump or two? | Q37222198 |
| | CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. | Q37305045 |
| | JAK3: a two-faced player in hematological disorders | Q37595688 |
| | Treating inflammation with the Janus kinase inhibitor CP-690,550. | Q37818691 |
| | Targeting acute myeloid leukemia cells with cytokines | Q38010537 |
| | Signalling by the βc family of cytokines | Q38093731 |
| | Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome | Q39993986 |
| | Activating alleles of JAK3 in acute megakaryoblastic leukemia | Q40255542 |
| | Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies | Q40531685 |
| | Critical sites for the interaction between IL-2Rgamma and JAK3 and the following signaling | Q40807661 |
| | Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia | Q44998179 |
| | Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers | Q45344494 |
| | T cell development and activation in Jak3-deficient mice | Q47992367 |
| | Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. | Q53307880 |
| | Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. | Q54408212 |
| | Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. | Q54522930 |
| | JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults | Q79657116 |
| | Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome | Q80209094 |
| | Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia | Q84019010 |
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2991-2999 | |
| P577 | publication date | 2014-08-11 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia | |
| P478 | volume | 34 | |